Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 24 Neoplasm Metastasis 3 Neoplasms by Site 2 Neoplasms 2 Multiple Endocrine Neoplasia Type 1 2 Breast Diseases 2 Unilateral Breast Neoplasms 1 Recurrence 1 Osteitis Deformans 1 Locally Advanced (Inoperable) or Metastatic Breast Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 HR+/HER2- Breast Cancer 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Breast Neoplasms, Male 1 Anatomic Stage II Breast Cancer AJCC v8 1 Advanced Metastatic Breast Cancer 1 Advanced Breast Cancer 1

Interventions

exemestane 4 Tamoxifen 3 Paclitaxel 3 Letrozole 3 Goserelin 3 Cyclophosphamide 3 pegfilgrastim 2 Radiotherapy 2 Pyridoxine 2 Leuprolide 2 Fluorouracil 2 Epirubicin 2 Capecitabine 2 Bevacizumab 2 Anastrozole 2 trastuzumab biosimilar HLX02 1 ribociclib 1 elacestrant 1 Zoledronic Acid 1 Trastuzumab 1 Taxes 1 Radiosurgery 1 Prochlorperazine 1 Palonosetron 1 PF-05280014 1 Ontruzant 1 Ogivri 1 Neoadjuvant Therapy 1 Mometasone Furoate 1 Methotrexate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Breast Neoplasms, Male × ribociclib × Clear all

NCT05827081 2026-06-03

Adjuvant WIDER

Novartis

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡